Press release
Metastatic Renal Cell Carcinoma Pipeline 2025: Pioneering Clinical Developments by 40+ Global Leaders - DelveInsight | Novartis Pharmaceuticals, Vaccibody, SillaJen, Chongqing Precision Biotech
Metastatic Renal Cell Carcinoma Pipeline 2025
With metastatic renal cell carcinoma (mRCC) reaching epidemic levels worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and other cancers, there is an increasing need for safer and more effective treatments. According to DelveInsight, the mRCC pipeline includes over 40 pharmaceutical and biotech companies developing more than 50 therapeutic candidates across various clinical and preclinical stages, highlighting significant innovation and dedication to addressing this major public health challenge.
DelveInsight's report, "Metastatic Renal Cell Carcinoma Pipeline Insight 2025," offers a comprehensive and strategic analysis of the R&D landscape, including clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. This report is an essential resource for researchers, healthcare investors, and decision-makers, providing insights into the evolving mRCC therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Metastatic renal cell carcinoma Drug Development [https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Key Takeaways from the Metastatic renal cell carcinoma Pipeline Report
*
DelveInsight's metastatic renal cell carcinoma (mRCC) pipeline report highlights a dynamic landscape with 40+ active companies developing over 50 therapeutic candidates for mRCC treatment.
*
In February 2025, updated results from a Phase 1 trial (NCT05122546) presented at the 2025 Genitourinary Cancers Symposium demonstrated that combining CBM588 with cabozantinib (Cabometyx) and nivolumab (Opdivo) improved progression-free survival (PFS) and objective response rate (ORR) in mRCC patients, although it did not significantly increase Bifidobacterium species levels.
*
In December 2024, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, announced dosing the first patient in its Phase 1 trial evaluating ADI-270 in patients with metastatic or advanced clear cell renal cell carcinoma (ccRCC).
*
Key companies actively developing mRCC therapies include AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., and others, all working to advance the mRCC treatment landscape.
*
Promising pipeline candidates in various stages of development include Olaparib, Atezolizumab, TP-1454, and others.
Metastatic renal cell carcinoma Overview:
Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer in adults, representing approximately 85% of kidney tumors. The disease often progresses silently, with only about 10% of patients exhibiting the classic symptoms of flank pain, hematuria (blood in the urine), and a palpable mass. Metastasis occurs in nearly one-third of RCC cases, commonly affecting the lungs, liver, bones, brain, and adrenal glands, though it can spread to almost any part of the body. Multiple organs are frequently involved.
Metastases may be present at the time of diagnosis or develop later, even after nephrectomy (surgical removal of the affected kidney). Around 20% to 50% of patients develop metastases post-nephrectomy, with a shorter interval to metastasis associated with a poorer prognosis. The overall outlook for patients with metastatic RCC remains poor, with a median survival of 6 to 12 months and only 10% to 20% surviving beyond two years.
Download the Metastatic renal cell carcinoma sample report to know in detail about the Metastatic renal cell carcinoma treatment market [https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Metastatic renal cell carcinoma Pipeline Analysis
The Metastatic renal cell carcinoma pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Metastatic renal cell carcinoma Market.
*
Categorizes Metastatic renal cell carcinoma therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Metastatic renal cell carcinoma drugs under development based on:
*
Stage of development
*
Metastatic renal cell carcinoma Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Metastatic renal cell carcinoma Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Metastatic renal cell carcinoma Licensing agreements
*
Funding and investment activities supporting future Metastatic renal cell carcinoma market advancement.
Unlock key insights into emerging Metastatic renal cell carcinoma therapies and market strategies here: https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Metastatic renal cell carcinoma Emerging Drugs
*
Olaparib: AstraZeneca
Olaparib is a potent and selective inhibitor of PARP1 and PARP2 enzymes. It works by targeting the defective DNA repair pathways in cancer cells with BRCA mutations, ultimately inducing cell death. Olaparib is approved for treating various BRCA-associated cancers, including ovarian, breast, pancreatic, and prostate cancers, with its initial FDA and EU approvals granted in December 2014. Currently, olaparib is being investigated in Phase II clinical trials for metastatic renal cell carcinoma.
*
Atezolizumab: Genentech
Atezolizumab is a humanized IgG antibody that binds to PD-L1, preventing its interaction with PD-1 and B7-1. By blocking this pathway, it restores immune system activity, enhancing the body's ability to target tumors, without inducing antibody-dependent cellular cytotoxicity. It is primarily used in patients whose tumors express PD-L1, who are unsuitable for platinum-based chemotherapy, or who have not responded to such treatments. Atezolizumab was FDA-approved on October 18, 2016, and is currently being evaluated in Phase III clinical trials for metastatic renal cell carcinoma.
*
TP-1454: Sumitomo Dainippon Pharma
TP-1454 is an investigational oral therapy that activates the M2 isoform of pyruvate kinase (PKM2). It is currently undergoing a Phase 1/1b clinical trial for patients with advanced or metastatic solid tumors (NCT04328740) and represents the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is a critical enzyme in glycolysis, with the PKM2 isoform playing a key role in the metabolic adaptations of cancer and immune cells, providing tumor cells with a metabolic advantage over the surrounding immune environment.
Metastatic renal cell carcinoma Pipeline Therapeutic Assessment
Metastatic renal cell carcinoma Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Metastatic renal cell carcinoma By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Metastatic renal cell carcinoma Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Metastatic renal cell carcinoma Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Metastatic renal cell carcinoma therapies and key Metastatic renal cell carcinoma companies: https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Metastatic renal cell carcinoma Current Treatment Patterns
4. Metastatic renal cell carcinoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Metastatic renal cell carcinoma Late-Stage Products (Phase-III)
7. Metastatic renal cell carcinoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic renal cell carcinoma Discontinued Products
13. Metastatic renal cell carcinoma Product Profiles
14. Metastatic renal cell carcinoma Key Companies
15. Metastatic renal cell carcinoma Key Products
16. Dormant and Discontinued Products
17. Metastatic renal cell carcinoma Unmet Needs
18. Metastatic renal cell carcinoma Future Perspectives
19. Metastatic renal cell carcinoma Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Metastatic renal cell carcinoma pipeline reports offerings: https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-renal-cell-carcinoma-pipeline-2025-pioneering-clinical-developments-by-40-global-leaders-delveinsight-novartis-pharmaceuticals-vaccibody-sillajen-chongqing-precision-biotech]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Renal Cell Carcinoma Pipeline 2025: Pioneering Clinical Developments by 40+ Global Leaders - DelveInsight | Novartis Pharmaceuticals, Vaccibody, SillaJen, Chongqing Precision Biotech here
News-ID: 4202740 • Views: …
More Releases from ABNewswire
C-MET Metastatic NSCLC Market: Epidemiology, Therapies, Companies, DelveInsight …
In 2023, the US accounted for the maximum share of the total C-MET Metastatic NSCLC Market in the 7MM, i.e., approximately 75%.
Emerging C-MET Metastatic NSCLC therapies-such as TABRECTA, TEPMETKO, Telisotuzumab Vedotin, REGN5093, REGN5093-M114, APL-101, MYTX-011, Glumetinib, Amivantamab, and Capmatinib Combination Therapy-are expected to drive growth in the C-MET Metastatic NSCLC market in the coming years.
DelveInsight has published a new report titled "C-MET Metastatic NSCLC - Market Insights, Epidemiology, and Market…
Relapsed/refractory acute myeloid leukemia (AML) Pipeline 2025: Pioneering Clini …
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML)- Pipeline Insight, 2025" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
With relapsed/refractory acute myeloid leukemia (AML) becoming increasingly prevalent worldwide and contributing to comorbidities such…
Pancreatic Ductal Adenocarcinoma Pipeline 2025: Pioneering Clinical Developments …
Key companies in pancreatic ductal adenocarcinoma market include Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, and Tarveda Therapeutics.
With Pancreatic Ductal Adenocarcinoma (PDAC) reaching epidemic levels globally and contributing to comorbidities such as diabetes, cardiovascular disease, and other cancers, there is an increasing demand for safer and more effective therapies. According to DelveInsight, the…
Oligometastatic Disease Market: Epidemiology, Therapies, Companies | DelveInsigh …
According to DelveInsight's patient-based forecasting model, the oligometastatic disease market size in the 7MM was around USD 1,900 million in 2023, which is expected to significantly increase over the forecast period (2024-2034), owing to an increase in the cases and the launch of new therapies.
Emerging therapies such as IMSA101, PNT2002 (177Lu-PNT2002), and others are expected to drive growth in the Oligometastatic Disease market in the coming years.
DelveInsight has released a…
More Releases for Metastatic
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth?
The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
